CN112969714A - 抗cd40抗体、其抗原结合片段及其医药用途 - Google Patents

抗cd40抗体、其抗原结合片段及其医药用途 Download PDF

Info

Publication number
CN112969714A
CN112969714A CN201980072271.9A CN201980072271A CN112969714A CN 112969714 A CN112969714 A CN 112969714A CN 201980072271 A CN201980072271 A CN 201980072271A CN 112969714 A CN112969714 A CN 112969714A
Authority
CN
China
Prior art keywords
seq
antibody
variable region
heavy chain
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980072271.9A
Other languages
English (en)
Other versions
CN112969714B (zh
Inventor
廖成
蒋家骅
徐祖朋
张连山
林�源
林侃
钱雪明
滕菲
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Publication of CN112969714A publication Critical patent/CN112969714A/zh
Application granted granted Critical
Publication of CN112969714B publication Critical patent/CN112969714B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

本公开涉及抗CD40抗体、其抗原结合片段及其医药用途。所述抗CD40抗体、其抗原结合片段的重链恒定区含有突变，所述突变使得抗CD40抗体丧失了其与FcγRIII结合的活性，同时增强了抗CD40抗体与FcγRIIB的结合，从而丧失了抗体依赖的细胞毒性(ADCC)，但是增强了FcγRIIB介导的抗体交联。重链恒定区中的突变导致增强了对CD40的激活，以及增强了树突细胞对抗原的递呈。本公开的抗CD40抗体及其抗原结合片段作为抗癌药物具有治疗CD40介导的疾病或病症的用途。

Description

PCT国内申请，说明书已公开。

Claims (23)

  1. PCT国内申请，权利要求书已公开。
CN201980072271.9A 2018-11-30 2019-11-29 抗cd40抗体、其抗原结合片段及其医药用途 Active CN112969714B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018114482281 2018-11-30
CN201811448228 2018-11-30
PCT/CN2019/121941 WO2020108611A1 (zh) 2018-11-30 2019-11-29 抗cd40抗体、其抗原结合片段及其医药用途

Publications (2)

Publication Number Publication Date
CN112969714A true CN112969714A (zh) 2021-06-15
CN112969714B CN112969714B (zh) 2022-11-22

Family

ID=70851924

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980072271.9A Active CN112969714B (zh) 2018-11-30 2019-11-29 抗cd40抗体、其抗原结合片段及其医药用途

Country Status (11)

Country Link
US (1) US20220025060A1 (zh)
EP (1) EP3892634A4 (zh)
JP (1) JP2022509156A (zh)
KR (1) KR20210099027A (zh)
CN (1) CN112969714B (zh)
AU (1) AU2019389354A1 (zh)
BR (1) BR112021009835A2 (zh)
CA (1) CA3120793A1 (zh)
MX (1) MX2021005823A (zh)
TW (1) TW202039558A (zh)
WO (1) WO2020108611A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023232036A1 (zh) * 2022-05-31 2023-12-07 明济生物制药（北京）有限公司 抗cd40抗体和抗pd-l1×cd40双特异抗体及其应用
WO2023236951A1 (zh) * 2022-06-06 2023-12-14 普米斯生物技术(珠海)有限公司 抗cd40抗体及其用途

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202330600A (zh) 2021-08-24 2023-08-01 大陸商江蘇恆瑞醫藥股份有限公司 Fap/cd40 結合分子及其醫藥用途
CN114573698B (zh) * 2022-03-16 2023-01-06 沈阳三生制药有限责任公司 一种FcRn抗原结合蛋白及其制备方法和应用
WO2024076969A1 (en) * 2022-10-04 2024-04-11 Memorial Sloan-Kettering Cancer Center Anti-cd40 antibodies and uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1922316A (zh) * 2003-12-25 2007-02-28 麒麟麦酒株式会社 抗cd40抗体突变体
US20070292439A1 (en) * 2004-04-27 2007-12-20 Novartis Vaccines And Diagnostics, Inc. Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use
CN106573981A (zh) * 2014-08-12 2017-04-19 鳄鱼生物科学公司 利用抗cd40抗体的组合疗法
US20180142030A1 (en) * 2015-06-29 2018-05-24 Bristol-Myers Squibb Company Antibodies to cd40
CN110177569A (zh) * 2017-03-30 2019-08-27 江苏恒瑞医药股份有限公司 抗体药物偶联物的制备方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10308991A (ja) 1997-05-07 1998-11-17 Mitsubishi Electric Corp スピーカー取付構造
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
US20030059427A1 (en) 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
EP1717251B1 (en) 2000-10-02 2012-01-18 Novartis Vaccines and Diagnostics, Inc. Therapy for B-cell malignancies using human anti-CD40 antibodies
EP2009027B1 (en) * 2001-04-27 2014-05-21 Kyowa Hakko Kirin Co., Ltd. Anti-CD40 monoclonal antibody
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
KR20070026522A (ko) 2004-04-27 2007-03-08 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 길항제 항-ｃｄ40 모노클론 항체 및 이들의 사용 방법
EP1919950A1 (en) 2004-07-15 2008-05-14 Xencor, Inc. Optimized fc variants
PL1885399T3 (pl) 2005-05-26 2011-04-29 Seattle Genetics Inc Humanizowane przeciwciała anty-CD40 i sposoby ich stosowania
EP1854810A1 (en) 2006-05-09 2007-11-14 PanGenetics B.V. Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody
EP2708557A1 (en) 2007-05-30 2014-03-19 Xencor, Inc. Method and compositions for inhibiting CD32B expressing cells
KR101760242B1 (ko) * 2010-03-31 2017-07-21 베링거 인겔하임 인터내셔날 게엠베하 항-ｃｄ40 항체
EP2566514A4 (en) * 2010-05-03 2013-11-27 Abbvie Inc METHODS OF INHIBITING FIBROSIS WITH ANTI-PAI-1 ANTIBODIES
SG194561A1 (en) 2011-04-21 2013-12-30 Bristol Myers Squibb Co Antibody polypeptides that antagonize cd40
CN113461819B (zh) 2011-04-29 2024-01-02 埃派斯进有限公司 抗-cd40抗体及其使用方法
GB201115280D0 (en) 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
DK2914627T3 (da) * 2012-10-30 2021-07-12 Apexigen Inc Anti-cd40-antistoffer og fremgangsmåder til anvendelse
AU2014232501C1 (en) 2013-03-15 2021-04-22 Xencor, Inc. Heterodimeric proteins
WO2015009853A1 (en) 2013-07-16 2015-01-22 University Of Louisville Research Foundation, Inc. Compositions for mucusal delivery, useful for treating papillomavirus infections
GB201322583D0 (en) * 2013-12-19 2014-02-05 Alligator Bioscience Ab Antibodies
CN114681608A (zh) * 2015-04-13 2022-07-01 戊瑞治疗有限公司 癌症组合疗法
DK3303395T3 (da) 2015-05-29 2020-01-27 Abbvie Inc Anti-cd40-antistoffer og anvendelser deraf
JP2018526977A (ja) * 2015-06-29 2018-09-20 ザ ロックフェラー ユニヴァーシティ アゴニスト活性が増強されたｃｄ４０に対する抗体
AU2016315873B2 (en) 2015-09-04 2022-08-18 Primatope Therapeutics Inc. Humanized anti-CD40 antibodies and uses thereof
CN106957366B (zh) * 2016-01-12 2022-02-01 上海昀怡健康科技发展有限公司 一种C5aR抗体及其制备方法和应用
HUE056670T2 (hu) * 2016-05-27 2022-02-28 Abbvie Biotherapeutics Inc Anti-CD40 antitestek és alkalmazásaik
EP3497130B1 (en) * 2016-08-12 2021-10-27 Merck Patent GmbH Combination therapy for cancer
WO2018219327A1 (zh) * 2017-06-01 2018-12-06 江苏恒瑞医药股份有限公司 抗cd40抗体、其抗原结合片段及其医药用途

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1922316A (zh) * 2003-12-25 2007-02-28 麒麟麦酒株式会社 抗cd40抗体突变体
US20070292439A1 (en) * 2004-04-27 2007-12-20 Novartis Vaccines And Diagnostics, Inc. Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use
CN106573981A (zh) * 2014-08-12 2017-04-19 鳄鱼生物科学公司 利用抗cd40抗体的组合疗法
US20180142030A1 (en) * 2015-06-29 2018-05-24 Bristol-Myers Squibb Company Antibodies to cd40
CN110177569A (zh) * 2017-03-30 2019-08-27 江苏恒瑞医药股份有限公司 抗体药物偶联物的制备方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GREGORY L BEATTY等: "Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists", 《EXPERT REVIEW OF CLINICAL IMMUNOLOGY》 *
RAUL ELGUETA等: "Molecular mechanism and function of CD40/CD40L engagement in the immune system", 《IMMUNOL REV》 *
罗龙龙等: "抗CD40单克隆抗体研究进展", 《中国实验血液学杂志》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023232036A1 (zh) * 2022-05-31 2023-12-07 明济生物制药（北京）有限公司 抗cd40抗体和抗pd-l1×cd40双特异抗体及其应用
WO2023236951A1 (zh) * 2022-06-06 2023-12-14 普米斯生物技术(珠海)有限公司 抗cd40抗体及其用途

Also Published As

Publication number Publication date
CA3120793A1 (en) 2020-06-04
TW202039558A (zh) 2020-11-01
JP2022509156A (ja) 2022-01-20
KR20210099027A (ko) 2021-08-11
EP3892634A1 (en) 2021-10-13
EP3892634A4 (en) 2022-11-16
CN112969714B (zh) 2022-11-22
BR112021009835A2 (pt) 2021-08-17
AU2019389354A1 (en) 2021-07-15
WO2020108611A1 (zh) 2020-06-04
MX2021005823A (es) 2021-07-15
US20220025060A1 (en) 2022-01-27

Similar Documents

Publication Publication Date Title
KR102365972B1 (ko) 항-pd-1 항체 및 이의 용도
CN110267989B (zh) 抗cd40抗体、其抗原结合片段及其医药用途
WO2015085847A1 (zh) Pd-1抗体、其抗原结合片段及其医药用途
CN112969714B (zh) 抗cd40抗体、其抗原结合片段及其医药用途
EP3712170A1 (en) Cd96 antibody, antigen-binding fragment and pharmaceutical use thereof
WO2019141268A1 (zh) 抗4-1bb抗体、其抗原结合片段及其医药用途
KR20180134397A (ko) 신규한 항-SIRPa 항체 및 이들의 치료학적 적용 방법
WO2019184935A1 (zh) 抗cd27抗体、其抗原结合片段及其医药用途
CN110461874B (zh) 抗gitr抗体、其抗原结合片段及其医药用途
WO2021228218A1 (zh) 抗cd25抗体、其抗原结合片段及其医药用途
JP7014783B2 (ja) 抗ｃｄ２７抗体、その抗原結合性フラグメント、およびそのものの医学的使用
RU2779128C2 (ru) Антитело к cd40, его антигенсвязывающий фрагмент и его медицинское применение
WO2021209066A1 (zh) 特异性抗原结合分子，其制备方法及医药用途
CN115947855A (zh) 抗cd24抗体的制备及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40051457

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant